| Attributes | Values |
|---|
| rdf:type
| |
| description
| - wetenschappelijk artikel (nl)
- наукова стаття, опублікована в лютому 1999 (uk)
- im Februar 1999 veröffentlichter wissenschaftlicher Artikel (de)
- artículu científicu espublizáu en febreru de 1999 (ast)
- artikull shkencor i botuar më 01 shkurt 1999 (sq)
- scientific article published on 01 February 1999 (en)
|
| publication date
| |
| publication date
| |
| language of work or name
| |
| language of work or name
| |
| author name string
| |
| author name string
| - G Singh
- T L Smith
- K K Hunt
- M I Ross
- G N Hortobagyi
- N Sneige
- K Dhingra
- R L Theriault
- T A Buchholz
- M D McNeese
- F C Ames
- H M Kuerer
- L A Newman
- S M Binkley
|
| rdfs:label
| - Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy (en)
- Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy (nl)
- Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy (sq)
|
| skos:prefLabel
| - Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy (en)
- Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy (nl)
- Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy (sq)
|
| name
| - Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy (en)
- Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy (nl)
- Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy (sq)
|
| author
| |
| author
| |
| title
| |
| title
| - Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy (en)
|
| page(s)
| |
| page(s)
| |
| instance of
| |
| instance of
| |
| main subject
| |
| main subject
| |
| PubMed ID
| |
| PubMed ID
| |
| PubMed ID
| |
| published in
| |
| published in
| |
| issue
| |
| volume
| |
| issue
| |
| volume
| |
| DOI
| |
| DOI
| |
| DOI
| - 10.1200/JCO.1999.17.2.460
|
| is about
of | |
| is cites work
of | - MRI in breast cancer therapy monitoring
- Dynamic contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer
- Baseline tumor oxygen saturation correlates with a pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy
- Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept
- ER, PgR, HER-2, Ki-67, topoisomerase IIα, and nm23-H1 proteins expression as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer
- Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania
- Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
- A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer
- Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy
- A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach
- Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease
- Concurrent chemoradiotherapy for locally advanced breast cancer-time for a new paradigm?
- Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study.
- Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival
- Neoadjuvant chemotherapy in breast cancers
- Prognostic value of residual node involvement in operable breast cancer after induction chemotherapy
- Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer
- A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer
- Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers
- Reduced Let-7a Is Associated with Chemoresistance in Primary Breast Cancer
- Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer
- Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets
- FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients.
|
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)